Company Expects Q2 2026 Revenue of Approximately $19.4 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17 hours ago
0mins
The company said, "Based on preliminary results, the Company expects to report second-quarter 2026 revenue of approximately $19.4 million, up approximately 31.5% from $14.75 million in Q2 2025, and first-half revenue of approximately $37.3 million, up approximately 31% from $28.46 million in H1 2025 - both the highest in the Company's history. Full financial results and commentary will be provided in the Company's Q2 2026 earnings release."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COSM
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cosmos Health Continues Stock Buyback Program
- Buyback Program Progress: Cosmos Health repurchased an additional 220,000 shares at an average price of approximately $0.2229 per share, bringing the total repurchased shares to 3,640,000 for about $700,000, indicating strong confidence in the stock's value.
- Program Details: The buyback program has a total allocation of $5 million and is set to expire on December 31, 2026, with potential for renewal based on market conditions, aimed at enhancing shareholder trust through capital returns.
- CEO's Confidence Statement: CEO Greg Siokas stated that the ongoing stock repurchases reflect the company's confidence in its operational strength and long-term potential, emphasizing that buybacks remain one of the most compelling investments available to the company.
- Global Business Expansion: In addition to stock buybacks, Cosmos Health, as a diversified global healthcare group, is continuously expanding its operations across Europe, Asia, and North America, focusing on innovation and R&D to enhance its market competitiveness.
See More
Cosmos Health Repurchases 77,000 Shares
- Repurchase Progress: Cosmos Health Inc. announced the buyback of an additional 77,000 shares at a price of $0.1956 per share, bringing the total repurchased shares to approximately 3.42 million at a total cost of $650,000, indicating the company's confidence in its stock value.
- Total Repurchase Limit: The share repurchase program has a total limit of $5 million and is expected to continue until December 31, 2026, demonstrating the company's intention to enhance shareholder value through ongoing market purchases.
- Stock Performance: Cosmos Health closed at $0.24 on Thursday, up 17.61% from the previous trading day, reflecting a positive market reaction to the company's buyback actions, although shares dipped 2.99% in after-hours trading.
- Market Signal: The company's ongoing stock repurchase not only boosts investor confidence but may also elevate the stock price in the future, further solidifying its market position in the healthcare sector.
See More
Cosmos Health Repurchases Additional 770,000 Shares
- Share Buyback Expansion: Cosmos Health has repurchased an additional 770,000 shares at an average price of approximately $0.1956 per share, bringing the total repurchased shares to 3.42 million for about $650,000, reflecting the company's confidence in its current stock price.
- Ongoing Buyback Program: Under a $5 million repurchase program, the company intends to continue open market purchases until December 31, 2026, indicating a proactive approach to capital utilization aimed at enhancing shareholder value.
- CEO Statement: CEO Greg Siokas stated that the steady expansion of buyback activities reflects the company's recognition of the intrinsic value of its diversified global platform, emphasizing the attractiveness of stock repurchases as a capital use.
- Global Expansion Strategy: By acquiring ZipDoctor, Cosmos Health enters the telehealth space and expands throughout Europe, Asia, and North America, showcasing its strategic positioning and growth potential in the global healthcare market.
See More
Cosmos Health Repurchases 2.65 Million Shares
- Share Repurchase Program: Cosmos Health announced the repurchase of 2.65 million shares for $500,000 at an average price of approximately $0.1887 per share, reflecting the company's confidence in its value and expected to enhance shareholder value.
- Background of Repurchase Plan: This buyback is part of a $5 million share repurchase program announced on June 30, 2026, which is set to expire on December 31, 2026, indicating the company's intention to continue repurchasing shares as market conditions permit.
- CEO's Confidence: CEO Greg Siokas stated that the current stock price significantly undervalues the company's assets and growth potential, viewing stock repurchase as one of the most attractive investments, aimed at enhancing long-term shareholder value.
- Multi-Layered Growth Strategy: Cosmos Health is committed to expanding its influence in the global healthcare market through active stock repurchases and a multi-layered growth strategy, particularly in the pharmaceutical and nutraceutical sectors.
See More
SOC Stock Plummets 56% After $450 Million Capital Raise Announcement
- SOC Capital Raise Impact: Sable Offshore Corp. (SOC) announced plans to raise up to $450 million through stock and convertible debt offerings, leading to a nearly 56% drop in stock price to $2.88 on Tuesday, reflecting a 91% decline from its 52-week high, indicating market concerns over its financial health.
- HTZ Price Decline Reasons: Hertz Global Holdings Inc. (HTZ) saw its stock price fall 1.5% to a 52-week low of $2.14 after analysts cut the price target to $3.50, citing rising vehicle depreciation costs and weakness in the used-car market, highlighting the financial pressures the company faces.
- COSM Stock Recovery: Cosmos Health Inc. (COSM) shares initially fell to a 52-week low of $0.16 following the announcement of a $5 million share buyback program, but recovered to close up 5.54%, reflecting market confidence in its future growth potential despite a 64.48% decline this year.
- Market Sentiment Shifts: Retail sentiment for SOC and COSM shifted from neutral to 'extremely bullish' over the past 24 hours, while HTZ sentiment also turned 'extremely bullish', despite SOC's over 73% decline this year, indicating divergent investor views on these companies' future performance.
See More
Cosmos Health Authorizes $5 Million Share Repurchase Program
- Repurchase Program Initiated: Cosmos Health has announced a share repurchase program authorized for up to $5 million, expected to be executed through open market and privately negotiated transactions, aimed at enhancing shareholder value and reflecting the company's confidence in its operational fundamentals.
- Market Capitalization Impact: The size of this repurchase program represents nearly half of the company's market capitalization as of June 29, 2026, indicating strong confidence in the undervaluation of its current stock price and future growth potential.
- Business Expansion Strategy: The company is accelerating its expansion into the U.S. market and new categories such as animal healthcare, coupled with record revenues and improving margins, which are expected to further enhance its competitive position in the market.
- Future Growth Outlook: CEO Greg Siok stated that the repurchase program not only acknowledges the company's operational momentum but also aims to create long-term value for shareholders, supporting the company's multi-layered growth strategy.
See More
Cosmos Health Continues Stock Buyback Program
- Buyback Program Progress: Cosmos Health repurchased an additional 220,000 shares at an average price of approximately $0.2229 per share, bringing the total repurchased shares to 3,640,000 for about $700,000, indicating strong confidence in the stock's value.
- Program Details: The buyback program has a total allocation of $5 million and is set to expire on December 31, 2026, with potential for renewal based on market conditions, aimed at enhancing shareholder trust through capital returns.
- CEO's Confidence Statement: CEO Greg Siokas stated that the ongoing stock repurchases reflect the company's confidence in its operational strength and long-term potential, emphasizing that buybacks remain one of the most compelling investments available to the company.
- Global Business Expansion: In addition to stock buybacks, Cosmos Health, as a diversified global healthcare group, is continuously expanding its operations across Europe, Asia, and North America, focusing on innovation and R&D to enhance its market competitiveness.
See More
Cosmos Health Repurchases 77,000 Shares
- Repurchase Progress: Cosmos Health Inc. announced the buyback of an additional 77,000 shares at a price of $0.1956 per share, bringing the total repurchased shares to approximately 3.42 million at a total cost of $650,000, indicating the company's confidence in its stock value.
- Total Repurchase Limit: The share repurchase program has a total limit of $5 million and is expected to continue until December 31, 2026, demonstrating the company's intention to enhance shareholder value through ongoing market purchases.
- Stock Performance: Cosmos Health closed at $0.24 on Thursday, up 17.61% from the previous trading day, reflecting a positive market reaction to the company's buyback actions, although shares dipped 2.99% in after-hours trading.
- Market Signal: The company's ongoing stock repurchase not only boosts investor confidence but may also elevate the stock price in the future, further solidifying its market position in the healthcare sector.
See More
Cosmos Health Repurchases Additional 770,000 Shares
- Share Buyback Expansion: Cosmos Health has repurchased an additional 770,000 shares at an average price of approximately $0.1956 per share, bringing the total repurchased shares to 3.42 million for about $650,000, reflecting the company's confidence in its current stock price.
- Ongoing Buyback Program: Under a $5 million repurchase program, the company intends to continue open market purchases until December 31, 2026, indicating a proactive approach to capital utilization aimed at enhancing shareholder value.
- CEO Statement: CEO Greg Siokas stated that the steady expansion of buyback activities reflects the company's recognition of the intrinsic value of its diversified global platform, emphasizing the attractiveness of stock repurchases as a capital use.
- Global Expansion Strategy: By acquiring ZipDoctor, Cosmos Health enters the telehealth space and expands throughout Europe, Asia, and North America, showcasing its strategic positioning and growth potential in the global healthcare market.
See More
Cosmos Health Repurchases 2.65 Million Shares
- Share Repurchase Program: Cosmos Health announced the repurchase of 2.65 million shares for $500,000 at an average price of approximately $0.1887 per share, reflecting the company's confidence in its value and expected to enhance shareholder value.
- Background of Repurchase Plan: This buyback is part of a $5 million share repurchase program announced on June 30, 2026, which is set to expire on December 31, 2026, indicating the company's intention to continue repurchasing shares as market conditions permit.
- CEO's Confidence: CEO Greg Siokas stated that the current stock price significantly undervalues the company's assets and growth potential, viewing stock repurchase as one of the most attractive investments, aimed at enhancing long-term shareholder value.
- Multi-Layered Growth Strategy: Cosmos Health is committed to expanding its influence in the global healthcare market through active stock repurchases and a multi-layered growth strategy, particularly in the pharmaceutical and nutraceutical sectors.
See More
SOC Stock Plummets 56% After $450 Million Capital Raise Announcement
- SOC Capital Raise Impact: Sable Offshore Corp. (SOC) announced plans to raise up to $450 million through stock and convertible debt offerings, leading to a nearly 56% drop in stock price to $2.88 on Tuesday, reflecting a 91% decline from its 52-week high, indicating market concerns over its financial health.
- HTZ Price Decline Reasons: Hertz Global Holdings Inc. (HTZ) saw its stock price fall 1.5% to a 52-week low of $2.14 after analysts cut the price target to $3.50, citing rising vehicle depreciation costs and weakness in the used-car market, highlighting the financial pressures the company faces.
- COSM Stock Recovery: Cosmos Health Inc. (COSM) shares initially fell to a 52-week low of $0.16 following the announcement of a $5 million share buyback program, but recovered to close up 5.54%, reflecting market confidence in its future growth potential despite a 64.48% decline this year.
- Market Sentiment Shifts: Retail sentiment for SOC and COSM shifted from neutral to 'extremely bullish' over the past 24 hours, while HTZ sentiment also turned 'extremely bullish', despite SOC's over 73% decline this year, indicating divergent investor views on these companies' future performance.
See More
Cosmos Health Authorizes $5 Million Share Repurchase Program
- Repurchase Program Initiated: Cosmos Health has announced a share repurchase program authorized for up to $5 million, expected to be executed through open market and privately negotiated transactions, aimed at enhancing shareholder value and reflecting the company's confidence in its operational fundamentals.
- Market Capitalization Impact: The size of this repurchase program represents nearly half of the company's market capitalization as of June 29, 2026, indicating strong confidence in the undervaluation of its current stock price and future growth potential.
- Business Expansion Strategy: The company is accelerating its expansion into the U.S. market and new categories such as animal healthcare, coupled with record revenues and improving margins, which are expected to further enhance its competitive position in the market.
- Future Growth Outlook: CEO Greg Siok stated that the repurchase program not only acknowledges the company's operational momentum but also aims to create long-term value for shareholders, supporting the company's multi-layered growth strategy.
See More
